Pediatric DBS Meta-Analysis Heads to Seizure in November

By Elena Vasquez

A six-author systematic review and meta-analysis on deep brain stimulation for pediatric drug-resistant epilepsy will appear in the November 2026 issue of Seizure: European Journal of Epilepsy, Volume 142. The paper carries the title "Deep brain stimulation outcomes in pediatric drug-resistant epilepsy: A systematic review and meta-analysis."

What does the paper actually examine?

The authors — Asmaa Mhanna, Michael A. Ciliberto, Sreenath Thati Ganganna, Brian J. Dlouhy, James WM Owens, and Aaron D. Boes — have pooled the available evidence on DBS applied to children whose seizures have not responded to antiseizure medication. A systematic review with meta-analysis is the appropriate instrument when the underlying studies are small and the field needs a pooled effect estimate rather than another single-center case series.

Pediatric drug-resistant epilepsy is a small population in absolute terms but a heavy one in clinical and family burden. DBS sits alongside vagus nerve stimulation, responsive neurostimulation, and dietary therapy as a palliative circuit-based option when resective surgery is not feasible. The pediatric subgroup has never had the equivalent of a large pivotal trial, so pooled evidence is what the literature can offer.

Why does a meta-analysis on pediatric DBS matter now?

Most of the published DBS literature in epilepsy comes from adults. The field has the long-term follow-up of the SANTE trial as its adult benchmark; pediatric cohorts exist but are scattered across small series, mixed targets (centromedian nucleus, anterior thalamus, hippocampus), and inconsistent outcome reporting. A meta-analysis is the instrument that turns that scatter into a single estimate with confidence intervals.

That matters in the pediatric epilepsy surgery conference room. Parents asking whether DBS is worth attempting in a child with Lennox-Gastaut syndrome or non-resectable cortical dysplasia deserve a pooled answer rather than three anecdotal case series. So do payers deciding on coverage for an implanted device.

What does DBS actually look like in this population?

In practice, pediatric DBS involves stereotactic implantation of depth electrodes, most commonly targeting the anterior nucleus of the thalamus, followed by staged device activation and serial programming over weeks to months. Scalp EEG, and in selected cases intracranial recordings, document the response. The work sits at the boundary of the operating room and the long-term monitoring unit, where seizure counts — not anecdotes — determine whether the therapy continues. Programming visits rely on parental seizure diaries and, where available, ambulatory EEG.

Pediatric DBS sits under the FDA-cleared adult indication for anterior thalamic stimulation in focal epilepsy; adolescent use is off-label rather than investigational. Meta-analytic pediatric evidence has lagged the adult literature by roughly a decade.

Who is behind the work?

The byline pairs pediatric epileptology expertise (Ciliberto, Owens) with functional neurosurgery (Dlouhy) and neurology research (Boes, Mhanna, Ganganna). That combination reads as deliberate: pediatric DBS outcomes depend on accurate seizure counting, and seizure counting in children depends on close pediatric neurology involvement. The paper appears in Seizure, a clinical journal with a focused epilepsy readership, rather than a general neurology title, which suits the topic.

What does this change for clinicians?

In the short term, nothing operational. The paper is forthcoming; readers cannot yet cite a pooled effect size from it. When it lands in print, the practical question is whether its pooled estimate tracks the direction of the established adult DBS signal, and whether any one pediatric stimulation target outperforms another on seizure reduction or tolerability. Both questions are answerable from the meta-analytic dataset, and both will shape counseling in clinic.

The reviewers' verdict, once published, will either tighten or loosen the case for offering DBS earlier in the pediatric surgical algorithm. Until then, the paper sits as a placeholder on every pediatric epileptologist's reading list — and a useful prompt to revisit institutional programming protocols in the meantime.